NGcGM3/VSSP vaccine as treatment for melanoma patients

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1237-1240

  Pérez, Kirenia ^a   Osorio, Marta ^b   Hernández, Julio ^c   Carr, Adriana ^a   Fernández, Luis Enrique ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^c Cardiocentro Ernesto Che Guevara Hospital Celestino Hernández Robau   (Cuba)

Author keywords

Clinical trial; Metastatic melanoma; NGlycolylated ganglioside; Vaccine

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; N GLYCOLYLATED GM3 GANGLIOSIDE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; CANCER IMMUNIZATION; CANCER PATIENT; CHILL; DELAYED TEST HYPERSENSITIVITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA; GENE OVEREXPRESSION; HUMAN; IMMUNE FUNCTION TEST; IMMUNOGENICITY; IMMUNOREACTIVITY; METASTATIC MELANOMA; MYALGIA; NOTE; OVERALL SURVIVAL; PAIN; SURVIVAL TIME; VITILIGO;

CLINICAL TRIAL; METASTATIC MELANOMA; NGLYCOLYLATED GANGLIOSIDE; VACCINE;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; G(M3) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; MELANOMA; PROTEOLIPIDS; TREATMENT OUTCOME;

EID: 84880664205     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24115     Document Type: Note

References (21)

1. Potapenko M, Shurin GV, de León J. Gangliosides as immunomodulators. Adv Exp Med Biol 2007; 601:195-203; PMID:17713006; http://dx.doi.org/10.1007/978-0-387-72005-0-20.
2. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19:241-7; PMID:10952412; http://dx.doi.org/10.1089/02724570050109639.
3. Stults CLM, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 1989; 179:167-214; PMID:2695766; http://dx.doi.org/10.1016/0076-6879(89)79122-9.
4. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996; 56:5309-18; PMID:8968075.
5. Portoukalian J, Zwingelstein G, Doré JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979; 94:19-23; PMID:436839; http://dx.doi.org/10.1111/j.1432-1033.1979. tb12866.x.
6. Fernández LE, Gabri MR, Guthmann MD, Gómez RE, Gold S, Fainboim L, et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397; PMID:21048926; http://dx.doi.org/10.1155/ 2010/814397.
7. Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008; 7:2033-41; PMID:18645013; http://dx.doi.org/10.1158/1535-7163.MCT-08-0222.
8. de León J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25-effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008; 20:591-600; PMID:18310617; http://dx.doi.org/10.1093/intimm/dxn018.
9. Labrada M, Clavell M, Bebelagua Y, León Jd, Alonso DF, Gabri MR, et al. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther 2010; 10:153-62; PMID:20088712; http://dx.doi.org/10.1517/14712590903443084.
10. Birklé S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85:455-63; PMID:12770784; http://dx.doi.org/10.1016/S0300-9084(03)00006-3.
11. Deng W, Li R, Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 2000; 92:912-7; PMID:10841826; http://dx.doi.org/10.1093/jnci/92.11.912.
12. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013; 104:43-7; PMID:23004020; http://dx.doi.org/10.1111/cas.12027.
13. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56:5165-71; PMID:8912852.
14. Oliva JP, Valdés Z, Casacó A, Pimentel G, González J, Alvarez I, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat 2006; 96:115-21; PMID:16322892; http://dx.doi.org/10. 1007/s10549-005-9064-0.
15. Blanco R, Cedeño M, Escobar X, Blanco D, Rengifo Ch, Frómeta M, et al. Immunorecognition of the 14F7 Mabraised against N-Glycolyl GM3 Ganglioside in some normal and malignant tissues from genitourinary system. ISRN Pathology 2011; Article ID 953803, 10 pages.
16. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, et al. Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011; 2011:245181; PMID:21941577; http://dx.doi.org/10. 1155/2011/245181.
17. Blanco R, Rengifo E, Cedeño M, Rengifo CE, Alonso DF, Carr A. Immunoreactivity of the 14F7 MAb raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol 2011; 2011:645641; PMID:21991524; .
18. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18:190-7; PMID:10501249; http://dx.doi.org/10.1016/S0264-410X(99)00219-4.
19. Blanco R, Rengifo E, Rengifo Ch, Cedeño M, Frómeta M, Carr A. immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-Glycolyl GM3 Ganglioside in some bening and malignant skin neoplasms. Dermatology 2011; Article ID 848909, 8 pages.
20. Osorio M, Gracia E, Rodríguez E, Saurez G, Arango MdelC, Noris E, et al. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008; 7:488-95; PMID:18285705; http://dx.doi.org/10.4161/cbt.7.4.5476.
21. Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res 2012; 4:341-5; PMID:23055778; http://dx.doi.org/10.2147/CMAR.S22617.